ArticleOncology letters2026
Skeletal muscle index at the third lumbar vertebra/BMI are positively associated with 1-year overall survival in male patients with hepatocellular carcinoma treated with immune checkpoint inhibitors.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Value of Skeletal Muscle Loss in Unresectable Hepatocellular Carcinoma Treated with TACE-Based Combination Therapy.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skeletal muscle loss is a hallmark of malnutrition and a well-established predictor of adverse clinical outcomes. However, its specific role as a risk factor and its prognostic relevance in patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) remain incompletely understood. The present study aimed to investigate the relationship between muscle mass (assessed via multiple skeletal muscle indices) and clinical outcomes in male patients with HCC receiving ICIs. A retrospective analysis of 195 male patients with HCC treated with ICIs was performed at Beijing Youan Hospital (Beijing, China). Transverse computed tomography images at the level of the third lumbar vertebra (L3) were analyzed with SliceOmatic software to quantify skeletal muscle parameters. Anthropometric, biochemical and prognostic data were collected and evaluated for association with survival. Among the 195 patients, 161 (82.56%) had hepatitis B virus infection and 163 (83.59%) had cirrhosis. Cumulative mortality at 6, 9 and 12 months was 4, 5 and 15%, respectively. Univariate analysis showed that lower body mass index (BMI) and higher values of L3 skeletal muscle index (L3-SMI), L3-SMI/weight, L3-SMI/height and L3-SMI/BMI were significantly associated with improved 1-year overall survival (OS; P<0.05). In multivariate Cox regression analysis, L3-SMI/BMI remained an independent predictor of 1-year OS (hazard ratio=0.02; 95% CI: 0.001-0.940; P=0.047). SHapley Additive exPlanations analysis further highlighted L3-SMI/BMI as a strong independent predictor for 1-year mortality. The area under the receiver operating characteristic curve of L3-SMI/BMI for predicting 1-year mortality was 0.86 (95% CI: 0.76-0.96), outperforming BMI, L3-SMI, L3-SMI/weight and L3-SMI/height. A higher L3-SMI/BMI ratio was a strong independent predictor of improved 1-year OS in male patients with HCC, predominantly Barcelona Clinic Liver Cancer stage A/B, treated with ICIs. These findings support the potential clinical utility of L3-SMI/BMI as a practical prognostic marker in this patient population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.